@Adaptimmune

Adaptimmune is a fully integrated cell therapy company focused on developing engineered cell therapies with the potential to redefine treatment of solid tumors.

adaptimmune.com
Joined July 2015
  • Tweets2.1K
  • Following292
  • Followers3.9K
1KMedia
Adaptimmune retweeted
Adaptimmune
@Adaptimmune6 Mar 2024
Today $ADAP reported financial results for Q4 and full year ended Dec. 31, 2023, and provided a business update on the progress made in establishing our sarcoma franchise. Release: bit.ly/48GMojA Call replay: bit.ly/4a0DfmZ #biotech #celltherapy #sarcoma
1
3
2
15
5,627
OCRA is pleased to welcome @Adaptimmune as the newest member of our Ovarian Cancer Industry Council. We look forward to our continued collaboration! Learn more about OCRA’s Ovarian Cancer Industry Council at bit.ly/3WGa2s3. #OvarianCancer
Teal graphic with the OCRA and Adaptimmune logos on it. Text reads as: OVARIAN CANCER INDUSTRY COUNCIL WELCOMES Adaptimmune

ALT Teal graphic with the OCRA and Adaptimmune logos on it. Text reads as: OVARIAN CANCER INDUSTRY COUNCIL WELCOMES Adaptimmune

1
1
2
6
2,865
Join the nationwide sarcoma community for the 2022 National Virtual @RacetoCureSarcoma. Show your support for much needed research and awareness. Register or learn more here: p2p.onecause.com/nationalvir… #curesarcoma #sarcoma #sarcomaawarenessmonth
4
1
9
SPEARHEAD-1: A Phase 2 Trial Brian Van Tine, MD @bvantine1 @WUSTLmed @WUSTL @Adaptimmune #ASCO21 #SPEARHEAD1 #Sarcoma #Cancer #Research oncologytube.com/video/40014…
SPEARHEAD-1: A Phase 2 Trial Brian Van Tine, MD @bvantine1 @WUSTLmed @WUSTL @Adaptimmune #ASCO21 #SPEARHEAD1 #Sarcoma #Cancer #Research

ALT SPEARHEAD-1: A Phase 2 Trial Brian Van Tine, MD @bvantine1 @WUSTLmed @WUSTL @Adaptimmune #ASCO21 #SPEARHEAD1 #Sarcoma #Cancer #Research

3
1
3
Bruno Sangro, MD, Ph.D. @ClinicaNavarra @Adaptimmune #livercancer The unmet need in HCC patients, the ADP-A2AFP complete response and its potential dlvr.it/RgyN9l
5
1
16
Replying to @DavidHongMD
@DavidHongMD presenting on @Adaptimmune SPEAR T-cell results for Synovial #Sarcoma #ASCO20. @OncoAlert @GinaDAmatoMD1 @raphaelyechieli @drkomanduri @EmilyJonczak @AndreaEspejoMD @drjunaidarsh @NGoelMD @PriscilaBCUM
1
9
1
21
After rebuilding the company's senior management team, the new CEO at Adaptimmune Therapeutics has the cell therapy developer on target for its first product launch. bizjournals.com/philadelphia…

After leadership overhaul, Adaptimmune targets first cell therapy product launch

The company's new CEO has a new leadership team in place and money in the bank as its works to advance its cell therapies for solid tumors.

bizjournals.com
5
2
We are stronger when we work together: #sarcoma patients, clinicians, researchers, scientists, and advocates. An entire session facilitating our common goals @myESMO #GIST #advocacy
10
24
Adaptimmune retweeted
Cryoport@cryoport9 Oct 2019
NEW partnership announcement: We’re proud to provide our unmatched biopharma logistics solutions to @Adaptimmune: cyrx.co/326UaSw
1
2
4
Jennifer Sampson, @Adaptimmune, gives a case study on the companies clinical studies #clinicaltrials #advancedtherapies
2
4
Adaptimmune retweeted
Vineti@vinetiworks28 Aug 2019
In #celltherapy #genetherapy, #data management takes on new complexity, because data represents @patients. In Sept, we’re publishing, speaking, and presenting on this critical topic. Connect with us via whitepaper, webinar, and conferences -- on our blog. buff.ly/2ZtUzvZ
2
1
The UK is a great place for #biotech 🧡 Join us in celebrating #biotechweek at the BIA Regulatory Innovation Conference on 17 September or at the Women in Biotech - Cambridge event on 26 September! 17 Sept: bia.me/2FQ7x0d 26 Sept: bia.me/2M9wQy1
European Biotech Week@biotechweek24 Jul 2019
Are you taking part in #biotechweek 2019? Don't see your country represented yet? Sign up your #event today and join the week-long celebrations of #biotech across Europe (23 - 29 September) - biotechweek.org #gbw2019 @BIOTECanada
5
6
Take a look at some of our key achievements in the @CGTCatapult Annual Review 2019, featuring @Adaptimmune @TCR2_Tx @KingsCollegeLon and @PhionTx #CGTCReview2019 - ow.ly/Nsd450v1IKq
6
4
July is Sarcoma Awareness Month. Soft tissue sarcomas are forms of cancer that develop in muscles, tendons, blood vessels, and other soft tissues. In 2019, an estimated 12,750 adults in the U.S. will be diagnosed with soft tissue sarcomas. bit.ly/2xJ2Oc0
2
1
Adaptimmune retweeted
Vineti@vinetiworks11 Jun 2019
“ “Mass customization’ ” has been possible in other industries, and we need to start focusing there in #celltherapy and #genetherapy.” @vinetiworks CEO Amy Duross Q&A with @ContractPharma buff.ly/2WybaSJ
1
1
Adaptimmune retweeted
Brad Loncar
@bradloncar31 May 2019
$ADAP’s Helen Tayton-Martin says the field is headed towards allogeneic therapies but they have a long way to go. Especially on issues like histocompatibility and reproducibility.
2
8
Sven Kili tells #ARM #MED19 conference session on #AdvancedTherapies about exploring the boundaries of #CellandGene
2
3
“I’ve never seen this amount of collaboration in oncology research in 25 years … it’s the most exciting time of my career” - Kimberly Freeman, VP Commercial at @Adaptimmune during our spotlight session on cell therapy for solid tumors #Med19
2
1
4
Great to see #oxford's @Adaptimmune on this list – at Cumnor, England
Kath Mackay@kath_mackay22 Mar 2019
11 companies supported by Innovate UK have been named on the @thesundaytimes and @MaseratiGB 2019 list of game-changing entrepreneurs: ow.ly/Q8Of101wJfQ @UKRI_News @KTNUK
2
1
7
Adaptimmune retweeted
@gulleyj1@gulleyj124 Jan 2019
Honored to be interviewed by Charles Graeber on Progress and Future Outlook of #Cancer #Immunotherapy. His book on #immunotherapy is a must read. #podcast theconferenceforum.org/immun…
4
2
14
Load more